Oncimmune Announces the Acquisition of Protagen Diagnostics AG, a Leader in Personalised Immuno-Profiling
Oncimmune Holdings plc (AIM:ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces it has acquired Protagen Diagnostics AG (“Protagen”) for a total consideration of up to £4.11 million